Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Pathogenesis, clinical manifestations, and diagnosis of pemphigus

Michael Hertl, MD
Cassian Sitaru, MD
Section Editor
John J Zone, MD
Deputy Editor
Abena O Ofori, MD


Pemphigus is defined as a group of life-threatening blistering disorders characterized by acantholysis (loss of keratinocyte to keratinocyte adhesion) that results in the formation of intraepithelial blisters in mucous membranes and skin [1]. The process of acantholysis is induced by the binding of circulating autoantibodies to intercellular adhesion molecules [1-3]. Patients with pemphigus develop mucosal erosions and/or flaccid bullae, erosions, or pustules on skin.

The four major entities of the pemphigus group include pemphigus vulgaris, pemphigus foliaceus, IgA pemphigus, and paraneoplastic pemphigus. The different forms of pemphigus are distinguished by their clinical features, associated autoantigens, and laboratory findings.

The pathogenesis, clinical features, and diagnosis of pemphigus will be discussed here. The management of pemphigus and greater detail on paraneoplastic pemphigus are reviewed separately. (See "Initial management of pemphigus vulgaris and pemphigus foliaceus" and "Management of refractory pemphigus vulgaris and pemphigus foliaceus" and "Paraneoplastic pemphigus".)


Common features of the major types of pemphigus are reviewed briefly below. A broader summary of the clinical and laboratory features of pemphigus is provided in the table (table 1).

Pemphigus vulgaris


Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Sep 2016. | This topic last updated: Apr 25, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
  1. Mihai S, Sitaru C. Immunopathology and molecular diagnosis of autoimmune bullous diseases. J Cell Mol Med 2007; 11:462.
  2. Sitaru C, Zillikens D. Mechanisms of blister induction by autoantibodies. Exp Dermatol 2005; 14:861.
  3. Hertl M, Eming R, Veldman C. T cell control in autoimmune bullous skin disorders. J Clin Invest 2006; 116:1159.
  4. Tsuruta D, Ishii N, Hamada T, et al. IgA pemphigus. Clin Dermatol 2011; 29:437.
  5. Kneisel A, Hertl M. Autoimmune bullous skin diseases. Part 1: Clinical manifestations. J Dtsch Dermatol Ges 2011; 9:844.
  6. Meyer N, Misery L. Geoepidemiologic considerations of auto-immune pemphigus. Autoimmun Rev 2010; 9:A379.
  7. Hans-Filho G, dos Santos V, Katayama JH, et al. An active focus of high prevalence of fogo selvagem on an Amerindian reservation in Brazil. Cooperative Group on Fogo Selvagem Research. J Invest Dermatol 1996; 107:68.
  8. Rocha-Alvarez R, Ortega-Loayza AG, Friedman H, et al. Endemic pemphigus vulgaris. Arch Dermatol 2007; 143:895.
  9. Joly P, Litrowski N. Pemphigus group (vulgaris, vegetans, foliaceus, herpetiformis, brasiliensis). Clin Dermatol 2011; 29:432.
  10. James KA, Culton DA, Diaz LA. Diagnosis and clinical features of pemphigus foliaceus. Dermatol Clin 2011; 29:405.
  11. Diaz LA, Sampaio SA, Rivitti EA, et al. Endemic pemphigus foliaceus (Fogo Selvagem): II. Current and historic epidemiologic studies. J Invest Dermatol 1989; 92:4.
  12. Brenner S, Wohl Y. A survey of sex differences in 249 pemphigus patients and possible explanations. Skinmed 2007; 6:163.
  13. Bastuji-Garin S, Souissi R, Blum L, et al. Comparative epidemiology of pemphigus in Tunisia and France: unusual incidence of pemphigus foliaceus in young Tunisian women. J Invest Dermatol 1995; 104:302.
  14. Abrèu-Velez AM, Hashimoto T, Bollag WB, et al. A unique form of endemic pemphigus in northern Colombia. J Am Acad Dermatol 2003; 49:599.
  15. Stanley JR, Amagai M. Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. N Engl J Med 2006; 355:1800.
  16. Hu CH, Michel B, Schiltz JR. Epidermal acantholysis induced in vitro by pemphigus autoantibody. An ultrastructural study. Am J Pathol 1978; 90:345.
  17. Schiltz JR, Michel B. Production of epidermal acantholysis in normal human skin in vitro by the IgG fraction from pemphigus serum. J Invest Dermatol 1976; 67:254.
  18. Schiltz JR, Michel B, Papay R. Pemphigus antibody interaction with human epidermal cells in culture. J Clin Invest 1978; 62:778.
  19. Supapannachart N, Mutasim DF. The distribution of IgA pemphigus antigen in human skin and the role of IgA anti-cell surface antibodies in the induction of intraepidermal acantholysis. Arch Dermatol 1993; 129:605.
  20. Anhalt GJ, Labib RS, Voorhees JJ, et al. Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306:1189.
  21. Ding X, Diaz LA, Fairley JA, et al. The anti-desmoglein 1 autoantibodies in pemphigus vulgaris sera are pathogenic. J Invest Dermatol 1999; 112:739.
  22. Roscoe JT, Diaz L, Sampaio SA, et al. Brazilian pemphigus foliaceus autoantibodies are pathogenic to BALB/c mice by passive transfer. J Invest Dermatol 1985; 85:538.
  23. Anhalt GJ, Kim SC, Stanley JR, et al. Paraneoplastic pemphigus. An autoimmune mucocutaneous disease associated with neoplasia. N Engl J Med 1990; 323:1729.
  24. Futamura S, Martins C, Rivitti EA, et al. Ultrastructural studies of acantholysis induced in vivo by passive transfer of IgG from endemic pemphigus foliaceus (Fogo Selvagem). J Invest Dermatol 1989; 93:480.
  25. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94:59.
  26. Amagai M, Hashimoto T, Green KJ, et al. Antigen-specific immunoadsorption of pathogenic autoantibodies in pemphigus foliaceus. J Invest Dermatol 1995; 104:895.
  27. Waschke J. The desmosome and pemphigus. Histochem Cell Biol 2008; 130:21.
  28. Getsios S, Waschke J, Borradori L, et al. From cell signaling to novel therapeutic concepts: international pemphigus meeting on advances in pemphigus research and therapy. J Invest Dermatol 2010; 130:1764.
  29. Grando SA. Pemphigus autoimmunity: hypotheses and realities. Autoimmunity 2012; 45:7.
  30. Amagai M, Tsunoda K, Zillikens D, et al. The clinical phenotype of pemphigus is defined by the anti-desmoglein autoantibody profile. J Am Acad Dermatol 1999; 40:167.
  31. Ding X, Aoki V, Mascaro JM Jr, et al. Mucosal and mucocutaneous (generalized) pemphigus vulgaris show distinct autoantibody profiles. J Invest Dermatol 1997; 109:592.
  32. Amagai M, Karpati S, Prussick R, et al. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90:919.
  33. Bhol K, Natarajan K, Nagarwalla N, et al. Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity. Proc Natl Acad Sci U S A 1995; 92:5239.
  34. Rock B, Martins CR, Theofilopoulos AN, et al. The pathogenic effect of IgG4 autoantibodies in endemic pemphigus foliaceus (fogo selvagem). N Engl J Med 1989; 320:1463.
  35. Funakoshi T, Lunardon L, Ellebrecht CT, et al. Enrichment of total serum IgG4 in patients with pemphigus. Br J Dermatol 2012; 167:1245.
  36. Mahoney MG, Wang Z, Rothenberger K, et al. Explanations for the clinical and microscopic localization of lesions in pemphigus foliaceus and vulgaris. J Clin Invest 1999; 103:461.
  37. Sardana K, Garg VK, Agarwal P. Is there an emergent need to modify the desmoglein compensation theory in pemphigus on the basis of Dsg ELISA data and alternative pathogenic mechanisms? Br J Dermatol 2013; 168:669.
  38. Jamora MJ, Jiao D, Bystryn JC. Antibodies to desmoglein 1 and 3, and the clinical phenotype of pemphigus vulgaris. J Am Acad Dermatol 2003; 48:976.
  39. Mao X, Nagler AR, Farber SA, et al. Autoimmunity to desmocollin 3 in pemphigus vulgaris. Am J Pathol 2010; 177:2724.
  40. Rafei D, Müller R, Ishii N, et al. IgG autoantibodies against desmocollin 3 in pemphigus sera induce loss of keratinocyte adhesion. Am J Pathol 2011; 178:718.
  41. Müller R, Heber B, Hashimoto T, et al. Autoantibodies against desmocollins in European patients with pemphigus. Clin Exp Dermatol 2009; 34:898.
  42. Tateishi C, Tsuruta D, Nakanishi T, et al. Antidesmocollin-1 antibody-positive, antidesmoglein antibody-negative pemphigus herpetiformis. J Am Acad Dermatol 2010; 63:e8.
  43. Kljuic A, Bazzi H, Sundberg JP, et al. Desmoglein 4 in hair follicle differentiation and epidermal adhesion: evidence from inherited hypotrichosis and acquired pemphigus vulgaris. Cell 2003; 113:249.
  44. Nguyen VT, Ndoye A, Grando SA. Pemphigus vulgaris antibody identifies pemphaxin. A novel keratinocyte annexin-like molecule binding acetylcholine. J Biol Chem 2000; 275:29466.
  45. Nguyen VT, Ndoye A, Grando SA. Novel human alpha9 acetylcholine receptor regulating keratinocyte adhesion is targeted by Pemphigus vulgaris autoimmunity. Am J Pathol 2000; 157:1377.
  46. Nguyen VT, Ndoye A, Shultz LD, et al. Antibodies against keratinocyte antigens other than desmogleins 1 and 3 can induce pemphigus vulgaris-like lesions. J Clin Invest 2000; 106:1467.
  47. Nagasaka T, Nishifuji K, Ota T, et al. Defining the pathogenic involvement of desmoglein 4 in pemphigus and staphylococcal scalded skin syndrome. J Clin Invest 2004; 114:1484.
  48. Hashimoto T. Immunopathology of IgA pemphigus. Clin Dermatol 2001; 19:683.
  49. Hashimoto T, Kiyokawa C, Mori O, et al. Human desmocollin 1 (Dsc1) is an autoantigen for the subcorneal pustular dermatosis type of IgA pemphigus. J Invest Dermatol 1997; 109:127.
  50. Hashimoto T, Komai A, Futei Y, et al. Detection of IgA autoantibodies to desmogleins by an enzyme-linked immunosorbent assay: the presence of new minor subtypes of IgA pemphigus. Arch Dermatol 2001; 137:735.
  51. Prost C, Intrator L, Wechsler J, et al. IgA autoantibodies bind to pemphigus vulgaris antigen in a case of intraepidermal neutrophilic IgA dermatosis. J Am Acad Dermatol 1991; 25:846.
  52. Wang J, Kwon J, Ding X, et al. Nonsecretory IgA1 autoantibodies targeting desmosomal component desmoglein 3 in intraepidermal neutrophilic IgA dermatosis. Am J Pathol 1997; 150:1901.
  53. Kárpáti S, Amagai M, Liu WL, et al. Identification of desmoglein 1 as autoantigen in a patient with intraepidermal neutrophilic IgA dermatosis type of IgA pemphigus. Exp Dermatol 2000; 9:224.
  54. Ishii N, Ishida-Yamamoto A, Hashimoto T. Immunolocalization of target autoantigens in IgA pemphigus. Clin Exp Dermatol 2004; 29:62.
  55. Firooz A, Mazhar A, Ahmed AR. Prevalence of autoimmune diseases in the family members of patients with pemphigus vulgaris. J Am Acad Dermatol 1994; 31:434.
  56. Abida O, Kallel-Sellami M, Joly P, et al. Anti-desmoglein 1 antibodies in healthy related and unrelated subjects and patients with pemphigus foliaceus in endemic and non-endemic areas from Tunisia. J Eur Acad Dermatol Venereol 2009; 23:1073.
  57. Brautbar C, Moscovitz M, Livshits T, et al. HLA-DRw4 in pemphigus vulgaris patients in Israel. Tissue Antigens 1980; 16:238.
  58. Ahmed AR, Wagner R, Khatri K, et al. Major histocompatibility complex haplotypes and class II genes in non-Jewish patients with pemphigus vulgaris. Proc Natl Acad Sci U S A 1991; 88:5056.
  59. Szafer F, Brautbar C, Tzfoni E, et al. Detection of disease-specific restriction fragment length polymorphisms in pemphigus vulgaris linked to the DQw1 and DQw3 alleles of the HLA-D region. Proc Natl Acad Sci U S A 1987; 84:6542.
  60. Sinha AA, Brautbar C, Szafer F, et al. A newly characterized HLA DQ beta allele associated with pemphigus vulgaris. Science 1988; 239:1026.
  61. Miyagawa S, Higashimine I, Iida T, et al. HLA-DRB1*04 and DRB1*14 alleles are associated with susceptibility to pemphigus among Japanese. J Invest Dermatol 1997; 109:615.
  62. Lombardi ML, Mercuro O, Ruocco V, et al. Common human leukocyte antigen alleles in pemphigus vulgaris and pemphigus foliaceus Italian patients. J Invest Dermatol 1999; 113:107.
  63. Petzl-Erler ML, Santamaria J. Are HLA class II genes controlling susceptibility and resistance to Brazilian pemphigus foliaceus (fogo selvagem)? Tissue Antigens 1989; 33:408.
  64. Cerna M, Fernandez-Viña M, Friedman H, et al. Genetic markers for susceptibility to endemic Brazilian pemphigus foliaceus (Fogo Selvagem) in Xavante Indians. Tissue Antigens 1993; 42:138.
  65. Abida O, Zitouni M, Kallel-Sellami M, et al. Tunisian endemic pemphigus foliaceus is associated with the HLA-DR3 gene: anti-desmoglein 1 antibody-positive healthy subjects bear protective alleles. Br J Dermatol 2009; 161:522.
  66. Pavoni DP, Roxo VM, Marquart Filho A, Petzl-Erler ML. Dissecting the associations of endemic pemphigus foliaceus (Fogo Selvagem) with HLA-DRB1 alleles and genotypes. Genes Immun 2003; 4:110.
  67. Kricheli D, David M, Frusic-Zlotkin M, et al. The distribution of pemphigus vulgaris-IgG subclasses and their reactivity with desmoglein 3 and 1 in pemphigus patients and their first-degree relatives. Br J Dermatol 2000; 143:337.
  68. Parameswaran A, Attwood K, Sato R, et al. Identification of a new disease cluster of pemphigus vulgaris with autoimmune thyroid disease, rheumatoid arthritis and type I diabetes. Br J Dermatol 2015; 172:729.
  69. Amagai M, Klaus-Kovtun V, Stanley JR. Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion. Cell 1991; 67:869.
  70. Aoki V, Millikan RC, Rivitti EA, et al. Environmental risk factors in endemic pemphigus foliaceus (fogo selvagem). J Investig Dermatol Symp Proc 2004; 9:34.
  71. Igawa K, Matsunaga T, Nishioka K. Involvement of UV-irradiation in pemphigus foliaceus. J Eur Acad Dermatol Venereol 2004; 18:216.
  72. Reis VM, Toledo RP, Lopez A, et al. UVB-induced acantholysis in endemic Pemphigus foliaceus (Fogo selvagem) and Pemphigus vulgaris. J Am Acad Dermatol 2000; 42:571.
  73. Muramatsu T, Iida T, Ko T, Shirai T. Pemphigus vulgaris exacerbated by exposure to sunlight. J Dermatol 1996; 23:559.
  74. Kawana S, Nishiyama S. Involvement of membrane attack complex of complement in UV-B-induced acantholysis in pemphigus. Arch Dermatol 1990; 126:623.
  75. Tan SR, McDermott MR, Castillo CJ, Sauder DN. Pemphigus vulgaris induced by electrical injury. Cutis 2006; 77:161.
  76. Tur E, Brenner S. Contributing exogenous factors in pemphigus. Int J Dermatol 1997; 36:888.
  77. Brenner S, Tur E, Shapiro J, et al. Pemphigus vulgaris: environmental factors. Occupational, behavioral, medical, and qualitative food frequency questionnaire. Int J Dermatol 2001; 40:562.
  78. Brenner S, Wohl Y. A burning issue: burns and other triggers in pemphigus. Cutis 2006; 77:145.
  79. Ruocco V, Pisani M. Induced pemphigus. Arch Dermatol Res 1982; 274:123.
  80. Ruocco V, Ruocco E, Lo Schiavo A, et al. Pemphigus: etiology, pathogenesis, and inducing or triggering factors: facts and controversies. Clin Dermatol 2013; 31:374.
  81. Inadomi T. A case of pemphigus foliaceus aggravated in an irradiated area by radiotherapy against breast cancer. Indian J Dermatol 2015; 60:93.
  82. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol 1998; 16:393.
  83. Marsden RA, Vanhegan RI, Walshe M, et al. Pemphigus foliaceus induced by penicillamine. Br Med J 1976; 2:1423.
  84. Brenner S, Goldberg I. Drug-induced pemphigus. Clin Dermatol 2011; 29:455.
  85. Feng S, Zhou W, Zhang J, Jin P. Analysis of 6 cases of drug-induced pemphigus. Eur J Dermatol 2011; 21:696.
  86. Mustafa MB, Porter SR, Smoller BR, Sitaru C. Oral mucosal manifestations of autoimmune skin diseases. Autoimmun Rev 2015; 14:930.
  87. Kavala M, Topaloğlu Demir F, Zindanci I, et al. Genital involvement in pemphigus vulgaris (PV): correlation with clinical and cervicovaginal Pap smear findings. J Am Acad Dermatol 2015; 73:655.
  88. Kavala M, Altıntaş S, Kocatürk E, et al. Ear, nose and throat involvement in patients with pemphigus vulgaris: correlation with severity, phenotype and disease activity. J Eur Acad Dermatol Venereol 2011; 25:1324.
  89. Torchia D, Romanelli P, Kerdel FA. Erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis associated with lupus erythematosus. J Am Acad Dermatol 2012; 67:417.
  90. Amagai M. Pemphigus. In: Dermatology, 3rd ed, Bolognia JL, Jorizzo JL, Schaffer JV, et al.. (Eds), Elsevier, 2012. Vol 1, p.461.
  91. Venugopal SS, Murrell DF. Diagnosis and clinical features of pemphigus vulgaris. Dermatol Clin 2011; 29:373.
  92. Yoshida K, Takae Y, Saito H, et al. Cutaneous type pemphigus vulgaris: a rare clinical phenotype of pemphigus. J Am Acad Dermatol 2005; 52:839.
  93. Shinkuma S, Nishie W, Shibaki A, et al. Cutaneous pemphigus vulgaris with skin features similar to the classic mucocutaneous type: a case report and review of the literature. Clin Exp Dermatol 2008; 33:724.
  94. Ohshima Y, Tamada Y, Matsumoto Y, Watanabe D. A case of cutaneous type pemphigus vulgaris. Int J Dermatol 2012; 51:1398.
  95. Payne AS, Stanley JR. Pemphigus. In: Fitzpatrick's Dermatology in General Medicine, 8th ed, Goldsmith LA, Katz SI, Gilchrest BA, et al. (Eds), McGraw Hill, 2012. Vol 1, p.586.
  96. Lebeau S, Müller R, Masouyé I, et al. Pemphigus herpetiformis: analysis of the autoantibody profile during the disease course with changes in the clinical phenotype. Clin Exp Dermatol 2010; 35:366.
  97. Robinson ND, Hashimoto T, Amagai M, Chan LS. The new pemphigus variants. J Am Acad Dermatol 1999; 40:649.
  98. Kasperkiewicz M, Kowalewski C, Jabłońska S. Pemphigus herpetiformis: from first description until now. J Am Acad Dermatol 2014; 70:780.
  99. Hashimoto T, Yasumoto S, Nagata Y, et al. Clinical, histopathological and immunological distinction in two cases of IgA pemphigus. Clin Exp Dermatol 2002; 27:636.
  100. Nousari HC, Deterding R, Wojtczack H, et al. The mechanism of respiratory failure in paraneoplastic pemphigus. N Engl J Med 1999; 340:1406.
  101. Gushi M, Yamamoto Y, Mine Y, et al. Neonatal pemphigus vulgaris. J Dermatol 2008; 35:529.
  102. Zhao CY, Chiang YZ, Murrell DF. Neonatal Autoimmune Blistering Disease: A Systematic Review. Pediatr Dermatol 2016; 33:367.
  103. Weedon D. The vesicobullous reaction pattern. In: Weedon's Skin Pathology, 3rd ed, Elsevier Limited, Edinburgh 2010. p.123.
  104. Ishii K, Amagai M, Hall RP, et al. Characterization of autoantibodies in pemphigus using antigen-specific enzyme-linked immunosorbent assays with baculovirus-expressed recombinant desmogleins. J Immunol 1997; 159:2010.
  105. Abasq C, Mouquet H, Gilbert D, et al. ELISA testing of anti-desmoglein 1 and 3 antibodies in the management of pemphigus. Arch Dermatol 2009; 145:529.
  106. Zone JJ. The value of desmoglein 1 and 3 antibody ELISA testing in patients with pemphigus. Arch Dermatol 2009; 145:585.
  107. Nagel A, Lang A, Engel D, et al. Clinical activity of pemphigus vulgaris relates to IgE autoantibodies against desmoglein 3. Clin Immunol 2010; 134:320.
  108. Hashimoto T, Ebihara T, Nishikawa T. Studies of autoantigens recognized by IgA anti-keratinocyte cell surface antibodies. J Dermatol Sci 1996; 12:10.
Topic Outline